Clinical Trial Update: SCT Plus Immune Therapy in Average Risk AML/MDS [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SCT plus immune therapy in average-risk acute myeloid leukemia and myelodysplastic syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• SCT plus immune therapy

Snippet

Sponsor: New York Medical College | Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED